RecruitingMigraine Disorders

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

Eligible age

6–11 yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.

Sponsor: Upsher-Smith Laboratories

✓ 1. Subject is a female or male 6 to 11 years of age, inclusive, at Visit 1 (Screening)
✓ 2. Subject weighs at least 17.0 kg and less than 50.0 kg at Visit 1 (Screening) based on 95 percentile weight for the age range.11
✓ 3. Subject has at least a 6-month history of headaches consistent with a diagnosis of migraine with or without aura (International Classification of Headache Disorders, 3rd Edition \[ICHD 3\]).
✓ 4. Subject had ≥8 self-reported headache days in the 28 days prior to Screening.
✓ 5. Subject has a PedMIDAS score \>10, indicating at least mild disruption in daily activities, and \<140, indicating extreme disability that may require more comprehensive, multi component therapy.

✕ 1. Subject has continuous migraines, defined as an unrelenting headache for a 28-day period.
✕ 2. Subject is currently receiving treatment or has used Botulinum toxin (Botox®) within 3 months prior to Visit 1 (Screening).
✕ 3. Subject is currently receiving migraine prevention medication and has initiated or changed the dose within 28 days of Screening or is unwilling to avoid making a change during the duration of the study.
✕ 4. Subject has previously failed an adequate trial of topiramate (at least 3 months duration at a clinically appropriate dose) for prophylaxis of migraine headache due to lack of efficacy or AEs.
✕ 5. Subject has previously failed an adequate trial of \>3 migraine preventative medications.
✕ 6. Subject has a known history of allergic reaction to topiramate or any excipient in Qudexy XR.
✕ 7. Subject has a diagnosis or history of disease that may interfere with safety or evaluation of the study drug.
✕ 8. Subject is currently using an investigational drug or device or has used such within 30 days prior to Visit 1.